Molecular Medicine

, Volume 21, Issue 1, pp 912–923 | Cite as

Aloperine Protects Mice against Ischemia-Reperfusion (IR)-Induced Renal Injury by Regulating PI3K/AKT/mTOR Signaling and AP-1 Activity

  • Shuang Hu
  • Yuxing Zhang
  • Meng Zhang
  • Yanchao Guo
  • Ping Yang
  • Shu Zhang
  • Sakine Simsekyilmaz
  • Jun-Fa Xu
  • Jinxiu Li
  • Xudong Xiang
  • Qilin Yu
  • Cong-Yi Wang
Research Article


Aloperine is a quinolizidine alkaloid extracted from the leaves of Sophora plants. It has been recognized with the potential to treat inflammatory and allergic diseases as well as tumors. In this report, we demonstrate that pretreatment with aloperine provided protection for mice against ischemia-reperfusion (IR)-induced acute renal injury as manifested by the attenuated inflammatory infiltration, reduced tubular apoptosis, and well-preserved renal function. Mechanistic studies revealed that aloperine selectively repressed IL-1β and IFN-γ expression by regulating PI3K/Akt/mTOR signaling and NF-κB transcriptional activity. However, aloperine did not show a perceptible impact on IL-6 and TGF-β expression and the related Jak2/Stat3 signaling. It was also noted that aloperine regulates AP-1 activity, through which it not only enhances SOD expression to increase reactive oxygen species (ROS) detoxification but also promotes the expression of antiapoptotic Bcl-2, thereby preventing tubular cells from IR-induced apoptosis. Collectively, our data suggest that administration of aloperine prior to IR insults, such as renal transplantation, could be a viable approach to prevent IR-induced injuries.



This work was supported by grants from the National Natural Science Foundation of China (81130014, 81471046 and 81530024), the European Foundation for the Study of Diabetes (EFSD)/Chinese Diabetes Society (CDC)/Lilly Program for Collaborative Diabetes Research between China and Europe, and Innovative Funding for Translational Research from Tongji Hospital.

Supplementary material

10020_2015_2101912_MOESM1_ESM.pdf (550 kb)
Supplementary material, approximately 549 KB.


  1. 1.
    Glaser DS. (1996) Acute renal failure. N. Engl. J. Med. 335:1321; author reply 1321–2.PubMedGoogle Scholar
  2. 2.
    Mangano CM, et al. (1998) Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. The Multicenter Study of Perioperative Ischemia Research Group. Ann. Intern. Med. 128:194–203.CrossRefGoogle Scholar
  3. 3.
    Aydin Z, van Zonneveld AJ, de Fijter JW, Rabelink TJ. (2007) New horizons in prevention and treatment of ischaemic injury to kidney transplants. Nephrol. Dial. Transplant. 22:342–6.CrossRefGoogle Scholar
  4. 4.
    Drazen JM, Ingelfinger JR, Curfman GD. (2003) Expression of concern: Schiffl H, et Al. Daily hemodialysis and the outcome of acute renal failure. N. Engl. J. Med. 346:305–10. N. Engl. J. Med. 348:2137.Google Scholar
  5. 5.
    Kazmers A, Jacobs L, Perkins A. (1997) The impact of complications after vascular surgery in Veterans Affairs Medical Centers. J. Surg. Res. 67:62–6.CrossRefGoogle Scholar
  6. 6.
    Chertow GM, et al. (2005) Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J. Am. Soc. Nephrol. 16:3365–70.CrossRefGoogle Scholar
  7. 7.
    Thurman JM, et al. (2006) Altered renal tubular expression of the complement inhibitor Crry permits complement activation after ischemia/reperfusion. J. Clin. Invest. 116:357–68.CrossRefGoogle Scholar
  8. 8.
    Li L, et al. (2007) NKT cell activation mediates neutrophil IFN-gamma production and renal ischemia-reperfusion injury. J. Immunol. 178:5899–911.CrossRefGoogle Scholar
  9. 9.
    Kelly KJ, et al. (1996) Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury. J. Clin. Invest. 97:1056–63.CrossRefGoogle Scholar
  10. 10.
    Day YJ, et al. (2005) Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated tissue protection: role of macrophages. Am. J. Physiol. Renal Physiol. 288:F722–31.CrossRefGoogle Scholar
  11. 11.
    Day YJ, et al. (2006) Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated tissue protection: the role of CD4+ T cells and IFN-gamma. J. Immunol. 176:3108–14.CrossRefGoogle Scholar
  12. 12.
    El Sabbahy M, Vaidya VS. (2011) Ischemic kidney injury and mechanisms of tissue repair. Wiley Interdiscip. Rev. Syst. Biol. Med. 3:606–18.CrossRefGoogle Scholar
  13. 13.
    Kusch A, et al. (2013) Novel signalling mechanisms and targets in renal ischaemia and reperfusion injury. Acta Physiol. (Oxf). 208:25–40.CrossRefGoogle Scholar
  14. 14.
    Fan LH, et al. (2012) Effect of ischemia preconditioning on renal ischemia/reperfusion injury in rats. Int. Braz. J. Urol. 38:842–54.CrossRefGoogle Scholar
  15. 15.
    Amura CR, et al. (2012) Complement activation and toll-like receptor-2 signaling contribute to cytokine production after renal ischemia/reperfusion. Mol. Immunol. 52:249–57.CrossRefGoogle Scholar
  16. 16.
    Lu CY, Hartono J, Senitko M, Chen J. (2007) The inflammatory response to ischemic acute kidney injury: a result of the ‘right stuff’ in the ‘wrong place’? Curr. Opin. Nephrol. Hypertens. 16:83–9.CrossRefGoogle Scholar
  17. 17.
    Thurman JM. (2007) Triggers of inflammation after renal ischemia/reperfusion. Clin. Immunol. 123:7–13.CrossRefGoogle Scholar
  18. 18.
    Liang CJ, et al. (2014) Endothelial progenitor cells derived from Wharton’s jelly of human umbilical cord attenuate ischemic acute kidney injury by increasing vascularization and decreasing apoptosis, inflammation, and fibrosis. Cell Transplant. 24:1363–77.CrossRefGoogle Scholar
  19. 19.
    Du T, Zhu YJ. (2014) The regulation of inflammatory mediators in acute kidney injury via exogenous mesenchymal stem cells. Mediators Inflamm. 2014:261697.CrossRefGoogle Scholar
  20. 20.
    Thadhani R, Pascual M, Bonventre JV. (1996) Acute renal failure. N. Engl. J. Med. 334:1448–60.CrossRefGoogle Scholar
  21. 21.
    Zhang CL, et al. (2012) Protective effects of garlic oil on hepatocarcinoma induced by N-nitrosodiethylamine in rats. Int. J. Biol. Sci. 8:363–74.CrossRefGoogle Scholar
  22. 22.
    Chatterjee PK, et al. (2000) Tempol, a membrane-permeable radical scavenger, reduces oxidant stress-mediated renal dysfunction and injury in the rat. Kidney Int. 58:658–73.CrossRefGoogle Scholar
  23. 23.
    Bo CJ, et al. (2013) Effects of ischemic preconditioning in the late phase on homing of endothelial progenitor cells in renal ischemia/reperfusion injury. Transplant Proc. 45:511–6.CrossRefGoogle Scholar
  24. 24.
    Li C, et al. (2011) Sophocarpine administration preserves myocardial function from ischemia-reperfusion in rats via NF-kappaB inactivation. J. Ethnopharmacol. 135:620–5.CrossRefGoogle Scholar
  25. 25.
    Zhou Y, et al. (2010) Total alkaloids of Sophora alopecuroides increases the expression of CD4+ CD25+ Tregs and IL-10 in rats with experimental colitis. Am. J. Chin. Med. 38:265–77.CrossRefGoogle Scholar
  26. 26.
    Lin Z, Huang CF, Liu XS, Jiang J. (2011) In vitro anti-tumour activities of quinolizidine alkaloids derived from Sophora flavescens Ait. Basic Clin. Pharmacol. Toxicol. 108:304–9.CrossRefGoogle Scholar
  27. 27.
    Yuan XY, et al. (2010) Effects and mechanisms of aloperine on 2, 4-dinitrofluorobenzene-induced allergic contact dermatitis in BALB/c mice. Eur. J. Pharmacol. 629:147–52.CrossRefGoogle Scholar
  28. 28.
    Zhou CC, et al. (1989) [Anti-inflammatory and anti-allergic action of aloperine]. [Article in Chinese]. Zhongguo Yao Li Xue Bao. 10:360–5.PubMedGoogle Scholar
  29. 29.
    Qavi HB, Wyde PR, Khan MA. (2002) In vitro Inhibition of HHV-6 replication by sophocarpines. Phytother. Res. 16:154–6.CrossRefGoogle Scholar
  30. 30.
    Qiong-Xu Y, et al. (2014) Aloperine attenuated neuropathic pain induced by chronic constriction injury via anti-oxidation activity and suppression of the nuclear factor kappa B pathway. Biochem. Biophys. Res. Commun. 451:568–73.CrossRefGoogle Scholar
  31. 31.
    Meldrum KK, et al. (2001) A novel model of ischemia in renal tubular cells which closely parallels in vivo injury. J. Surg. Res. 99:288–93.CrossRefGoogle Scholar
  32. 32.
    Wang LT, et al. (2013) Protective role of AMP-activated protein kinase-evoked autophagy on an in vitro model of ischemia/reperfusion-induced renal tubular cell injury. PLoS One. 8:e79814.CrossRefGoogle Scholar
  33. 33.
    Li J, et al. (2011) Neutralization of the extracellular HMGB1 released by ischaemic damaged renal cells protects against renal ischaemia-reperfusion injury. Nephrol. Dial. Transplant. 26:469–78.CrossRefGoogle Scholar
  34. 34.
    Zhong J, et al. (2014) MBD2 regulates TH17 differentiation and experimental autoimmune encephalomyelitis by controlling the homeostasis of T-bet/Hlx axis. J. Autoimmun. 53:95–104.CrossRefGoogle Scholar
  35. 35.
    Zou R, et al. (2014) Telmisartan protects 5/6 Nx rats against renal injury by enhancing nNOS-derived NO generation via regulation of PPAR-gamma signaling. Am. J. Transl. Res. 6:517–27.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Zheng X, et al. (2006) Preventing renal ischemia-reperfusion injury using small interfering RNA by targeting complement 3 gene. Am. J. Transplant. 6:2099–108.CrossRefGoogle Scholar
  37. 37.
    Yang J, et al. (2013) TJ0711, a novel vasodilatory beta-blocker, protects SHR rats against hypertension induced renal injury. Am. J. Transl. Res. 5:279–90.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Zhang S, et al. (2012) Loss of dicer exacerbates cyclophosphamide-induced bladder overactivity by enhancing purinergic signaling. Am. J. Pathol. 181:937–46.CrossRefGoogle Scholar
  39. 39.
    Pandey D, et al. (2011) SUMO1 negatively regulates reactive oxygen species production from NADPH oxidases. Arterioscler. Thromb. Vasc. Biol. 31:1634–42.CrossRefGoogle Scholar
  40. 40.
    Yang P, et al. (2013) Loss of Jak2 impairs endothelial function by attenuating Raf-1/MEK1/Sp-1 signaling along with altered eNOS activities. Am. J. Pathol. 183:617–25.CrossRefGoogle Scholar
  41. 41.
    Zhang S, et al. (2009) HMGB1, an innate alarmin, in the pathogenesis of type 1 diabetes. Int. J. Clin. Exp. Pathol. 3:24–38.PubMedGoogle Scholar
  42. 42.
    Sharfuddin AA, Molitoris BA. (2011) Pathophysiology of ischemic acute kidney injury. Nat. Rev. Nephrol. 7:189–200.CrossRefGoogle Scholar
  43. 43.
    Devarajan P. (2006) Update on mechanisms of ischemic acute kidney injury. J. Am. Soc. Nephrol. 17:1503–20.CrossRefGoogle Scholar
  44. 44.
    Kim J, et al. (2006) Orchiectomy attenuates postischemic oxidative stress and ischemia/reperfusion injury in mice. A role for manganese superoxide dismutase. J Biol. Chem. 281:20349–56.CrossRefGoogle Scholar
  45. 45.
    Wang X, et al. (2009) c-Fos enhances the survival of thymocytes during positive selection by upregulating Bcl-2. Cell Res. 19:340–7.CrossRefGoogle Scholar
  46. 46.
    Wang ZY, et al. (2005) Regulation of IL-10 gene expression in Th2 cells by Jun proteins. J. Immunol. 174:2098–105.CrossRefGoogle Scholar
  47. 47.
    Yu JH, Kim KH, Kim H. (2008) SOCS 3 and PPAR-gamma ligands inhibit the expression of IL-6 and TGF-beta1 by regulating JAK2/STAT3 signaling in pancreas. Int. J. Biochem. Cell Biol. 40:677–88.CrossRefGoogle Scholar
  48. 48.
    Schroder K, Tschopp J. (2010) The inflammasomes. Cell. 140:821–32.CrossRefGoogle Scholar
  49. 49.
    Zhang J. (2007) Yin and yang interplay of IFN-gamma in inflammation and autoimmune disease. J. Clin. Invest. 117:871–3.CrossRefGoogle Scholar
  50. 50.
    Iyer SS, Cheng G. (2012) Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit. Rev. Immunol. 32:23–63.CrossRefGoogle Scholar
  51. 51.
    Kezic A, Becker JU, Thaiss F. (2013) The effect of mTOR-inhibition on NF-kappaB activity in kidney ischemia-reperfusion injury in mice. Transplant Proc. 45:1708–14.CrossRefGoogle Scholar
  52. 52.
    Zhang J, et al. (2013) Administration of dexamethasone protects mice against ischemia/reperfusion induced renal injury by suppressing PI3K/AKT signaling. Int. J. Clin. Exp. Pathol. 6:2366–75.PubMedPubMedCentralGoogle Scholar
  53. 53.
    Chen J, et al. (2013) Low molecular weight fucoidan against renal ischemia-reperfusion injury via inhibition of the MAPK signaling pathway. PLoS One. 8:e56224.CrossRefGoogle Scholar
  54. 54.
    Hao W, et al. (2006) Induction of apoptosis by the Ste20-like kinase SLK, a germinal center kinase that activates apoptosis signal-regulating kinase and p38. J. Biol. Chem. 281:3075–84.CrossRefGoogle Scholar
  55. 55.
    Anitha M, et al. (2006) GDNF rescues hyperglycemia-induced diabetic enteric neuropathy through activation of the PI3K/Akt pathway. J. Clin. Invest. 116:344–56.CrossRefGoogle Scholar
  56. 56.
    Chen L, et al. (2013) SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell. 23:826–38.CrossRefGoogle Scholar
  57. 57.
    Le Belle JE, et al. (2011) Proliferative neural stem cells have high endogenous ROS levels that regulate self-renewal and neurogenesis in a PI3K/Akt-dependant manner. Cell Stem Cell. 8:59–71.CrossRefGoogle Scholar
  58. 58.
    She QB, et al. (2005) The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell. 8:287–97.CrossRefGoogle Scholar
  59. 59.
    Hemmings BA, Restuccia DF. (2012) PI3K-PKB/Akt pathway. Cold Spring Harb. Perspect. Biol. 4:a011189.CrossRefGoogle Scholar
  60. 60.
    Hirsch E, et al. (2000) Central role for G proteincoupled phosphoinositide 3-kinase gamma in inflammation. Science. 287:1049–53.CrossRefGoogle Scholar
  61. 61.
    Weichhart T, Saemann MD. (2008) The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications. Ann Rheum Dis. 67 Suppl 3:iii70–4.PubMedGoogle Scholar
  62. 62.
    Doukas J, et al. (2006) Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury. Proc. Natl. Acad. Sci. U. S. A. 103:19866–71.CrossRefGoogle Scholar
  63. 63.
    Ravingerova T, et al. (2012) PPAR-alpha activation as a preconditioning-like intervention in rats in vivo confers myocardial protection against acute ischaemia-reperfusion injury: involvement of PI3K-Akt. Can. J. Physiol. Pharmacol. 90:1135–44.CrossRefGoogle Scholar
  64. 64.
    Libermann TA, Baltimore D. (1990) Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol. Cell. Biol. 10:2327–34.CrossRefGoogle Scholar
  65. 65.
    Liang HL, et al. (2009) Partial attenuation of cytotoxicity and apoptosis by SOD1 in ischemic renal epithelial cells. Apoptosis. 14:1176–89.CrossRefGoogle Scholar
  66. 66.
    Zhang L, et al. (2014) Aloperine induces G2/M phase cell cycle arrest and apoptosis in HCT116 human colon cancer cells. Int. J. Mol. Med. 33:1613–20.CrossRefGoogle Scholar
  67. 67.
    Rui T, Kvietys PR. (2005) NFkappaB and AP-1 differentially contribute to the induction of Mn-SOD and eNOS during the development of oxidant tolerance. FASEB J. 19:1908–10.CrossRefGoogle Scholar
  68. 68.
    Gu J, et al. (2011) Dexmedetomidine provides renoprotection against ischemia-reperfusion injury in mice. Crit. Care. 15:R153.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2015

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (

Authors and Affiliations

  • Shuang Hu
    • 1
  • Yuxing Zhang
    • 1
  • Meng Zhang
    • 1
  • Yanchao Guo
    • 1
  • Ping Yang
    • 1
  • Shu Zhang
    • 1
  • Sakine Simsekyilmaz
    • 1
  • Jun-Fa Xu
    • 2
  • Jinxiu Li
    • 3
  • Xudong Xiang
    • 3
  • Qilin Yu
    • 1
  • Cong-Yi Wang
    • 1
    • 2
    • 3
  1. 1.The Center for Biomedical Research, Tongji HospitalHuazhong University of Science and TechnologyWuhanChina
  2. 2.Department of Clinical Immunology, Institute of Laboratory MedicineGuangdong Medical CollegeDongguanChina
  3. 3.Department of Emergency Medicine, Institute of Emergency Medicine and Rare Diseases, the Second Xiangya HospitalCentral South UniversityChangshaChina

Personalised recommendations